[논문]EZH2 as a Potential Target for NAFLD Therapy

Lim, Hyun Jung; Kim, Mirang

doi:10.3390/ijms21228617

[해외논문] EZH2 as a Potential Target for NAFLD Therapy 원문보기

International journal of molecular sciences, v.21 no.22, 2020년, pp.8617 -

Lim, Hyun Jung (Personalized Genomic Medicine Research Center, Korea Research Institute of Bioscience and Biotechnology (KRIBB), Daejeon 34141, Korea) , Kim, Mirang (hjlim@kribb.re.kr)

Abstract ▼ AI-Helper

Non-alcoholic fatty liver disease (NAFLD) is a complex disease that is affected by genetic predisposition and epigenetic modification. Deregulation of epigenetic pathways is now recognized as a frequent event in NAFLD, and understanding the mechanistic roles of these epigenetic factors may lead to new strategies for NAFLD treatment. Enhancer of zeste homolog 2 (EZH2) catalyzes methylation on Lys 27 of histone H3, which leads to chromatin compaction and gene silencing. EZH2 regulates embryonic development and cell lineage determination and is related to many human diseases. Recent studies show that EZH2 has critical roles in liver development, homeostasis, and regeneration. Moreover, aberrant activation of EZH2 promotes NAFLD progression. Several EZH2 inhibitors have been developed and studied both in vitro and in clinical trials. In this review, we summarize our current understanding of the role of EZH2 in NAFLD and highlight its potential as a novel therapeutic target for NAFLD treatment.

Keyword

참고문헌 (114)

1. Cotter T.G. Rinella M. Nonalcoholic fatty liver disease 2020: The state of the disease Gastroenterology 2020 158 1851 1864 10.1053/j.gastro.2020.01.052 32061595

상세보기
2. Swinburn B.A. Sacks G. Hall K.D. McPherson K. Finegood D.T. Moodie M.L. Gortmaker S.L. The global obesity pandemic: Shaped by global drivers and local environments Lancet 2011 378 804 814 10.1016/S0140-6736(11)60813-1 21872749

상세보기
3. Dowman J.K. Tomlinson J.W. Newsome P.N. Pathogenesis of non-alcoholic fatty liver disease QJM 2010 103 71 83 10.1093/qjmed/hcp158 19914930

상세보기
4. Day C.P. James O.F. Steatohepatitis: A tale of two “hits”? Gastroenterology 1998 114 842 845 10.1016/S0016-5085(98)70599-2 9547102

상세보기
5. Day C.P. From fat to inflammation Gastroenterology 2006 130 207 210 10.1053/j.gastro.2005.11.017 16401483

상세보기
6. Buzzetti E. Pinzani M. Tsochatzis E.A. The multiple-hit pathogenesis of non-alcoholic fatty liver disease (NAFLD) Metabolism 2016 65 1038 1048 10.1016/j.metabol.2015.12.012 26823198

상세보기
7. Ludwig J. Viggiano T.R. McGill D.B. Oh B.J. Nonalcoholic steatohepatitis: Mayo clinic experiences with a hitherto unnamed disease Mayo. Clin. Proc. 1980 55 434 438 7382552

상세보기
8. Eslam M. Sanyal A.J. George J. International Consensus P. MAFLD: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease Gastroenterology 2020 158 1999 2014.e1991 10.1053/j.gastro.2019.11.312 32044314

상세보기
9. Adams L.A. Lymp J.F. St Sauver J. Sanderson S.O. Lindor K.D. Feldstein A. Angulo P. The natural history of nonalcoholic fatty liver disease: A population-based cohort study Gastroenterology 2005 129 113 121 10.1053/j.gastro.2005.04.014 16012941

상세보기
10. Fassio E. Alvarez E. Dominguez N. Landeira G. Longo C. Natural history of nonalcoholic steatohepatitis: A longitudinal study of repeat liver biopsies Hepatology 2004 40 820 826 10.1002/hep.20410 15382171

상세보기
11. Koopman K.E. Caan M.W. Nederveen A.J. Pels A. Ackermans M.T. Fliers E. la Fleur S.E. Serlie M.J. Hypercaloric diets with increased meal frequency, but not meal size, increase intrahepatic triglycerides: A randomized controlled trial Hepatology 2014 60 545 553 10.1002/hep.27149 24668862

상세보기
12. Vilar-Gomez E. Martinez-Perez Y. Calzadilla-Bertot L. Torres-Gonzalez A. Gra-Oramas B. Gonzalez-Fabian L. Friedman S.L. Diago M. Romero-Gomez M. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis Gastroenterology 2015 149 367 378 10.1053/j.gastro.2015.04.005 25865049

상세보기
13. Pydyn N. Miekus K. Jura J. Kotlinowski J. New therapeutic strategies in nonalcoholic fatty liver disease: A focus on promising drugs for nonalcoholic steatohepatitis Pharmacol. Rep. 2020 72 1 12 10.1007/s43440-019-00020-1 32016853

상세보기
14. Munteanu M.A. Nagy G.A. Mircea P.A. Current management of NAFLD Clujul. Med. 2016 89 19 23 10.15386/cjmed-539 27004021

상세보기
15. Oseini A.M. Sanyal A.J. Therapies in non-alcoholic steatohepatitis (NASH) Liver Int. 2017 37 Suppl. 1 97 103 10.1111/liv.13302 28052626

상세보기
16. Musso G. Cassader M. Gambino R. Non-alcoholic steatohepatitis: Emerging molecular targets and therapeutic strategies Nat. Rev. Drug Discov. 2016 15 249 274 10.1038/nrd.2015.3 26794269

상세보기
17. Bugianesi E. Moscatiello S. Ciaravella M.F. Marchesini G. Insulin resistance in nonalcoholic fatty liver disease Curr. Pharm. Des. 2010 16 1941 1951 10.2174/138161210791208875 20370677

상세보기
18. Mendez-Sanchez N. Cruz-Ramon V.C. Ramirez-Perez O.L. Hwang J.P. Barranco-Fragoso B. Cordova-Gallardo J. New aspects of lipotoxicity in nonalcoholic steatohepatitis Int. J. Mol. Sci. 2018 19 2034 10.3390/ijms19072034

상세보기
19. Bird A. Perceptions of epigenetics Nature 2007 447 396 398 10.1038/nature05913 17522671

상세보기
20. Egger G. Liang G. Aparicio A. Jones P.A. Epigenetics in human disease and prospects for epigenetic therapy Nature 2004 429 457 463 10.1038/nature02625 15164071

상세보기
21. Lu Y. Chan Y.T. Tan H.Y. Li S. Wang N. Feng Y. Epigenetic regulation in human cancer: The potential role of epi-drug in cancer therapy Mol. Cancer 2020 19 79 10.1186/s12943-020-01197-3 32340605

상세보기
22. Kim K.H. Roberts C.W. Targeting EZH2 in cancer Nat. Med. 2016 22 128 134 10.1038/nm.4036 26845405

상세보기
23. Eslam M. Valenti L. Romeo S. Genetics and epigenetics of NAFLD and NASH: Clinical impact J. Hepatol. 2018 68 268 279 10.1016/j.jhep.2017.09.003 29122391

상세보기
24. Romeo S. Kozlitina J. Xing C. Pertsemlidis A. Cox D. Pennacchio L.A. Boerwinkle E. Cohen J.C. Hobbs H.H. Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease Nat. Genet. 2008 40 1461 1465 10.1038/ng.257 18820647

상세보기
25. Del Campo J.A. Gallego-Duran R. Gallego P. Grande L. Genetic and epigenetic regulation in nonalcoholic fatty liver disease (NAFLD) Int. J. Mol. Sci. 2018 19 911 10.3390/ijms19030911 29562725

상세보기
26. Kim M. DNA methylation: A cause and consequence of type 2 diabetes Genom. Inform. 2019 17 e38 10.5808/GI.2019.17.4.e38 31896238

원문보기 상세보기
27. Murphy S.K. Yang H. Moylan C.A. Pang H. Dellinger A. Abdelmalek M.F. Garrett M.E. Ashley-Koch A. Suzuki A. Tillmann H.L. Relationship between methylome and transcriptome in patients with nonalcoholic fatty liver disease Gastroenterology 2013 145 1076 1087 10.1053/j.gastro.2013.07.047 23916847

상세보기
28. Hotta K. Kitamoto T. Kitamoto A. Ogawa Y. Honda Y. Kessoku T. Yoneda M. Imajo K. Tomeno W. Saito S. Identification of the genomic region under epigenetic regulation during non-alcoholic fatty liver disease progression Hepatol. Res. 2018 48 E320 E334 10.1111/hepr.12992 29059699

상세보기
29. Ahrens M. Ammerpohl O. von Schonfels W. Kolarova J. Bens S. Itzel T. Teufel A. Herrmann A. Brosch M. Hinrichsen H. DNA methylation analysis in nonalcoholic fatty liver disease suggests distinct disease-specific and remodeling signatures after bariatric surgery Cell Metab. 2013 18 296 302 10.1016/j.cmet.2013.07.004 23931760

상세보기
30. Kitamoto T. Kitamoto A. Ogawa Y. Honda Y. Imajo K. Saito S. Yoneda M. Nakamura T. Nakajima A. Hotta K. Targeted-bisulfite sequence analysis of the methylation of CpG islands in genes encoding PNPLA3 , SAMM50 , and PARVB of patients with non-alcoholic fatty liver disease J. Hepatol. 2015 63 494 502 10.1016/j.jhep.2015.02.049 25776890

상세보기
31. Walle P. Mannisto V. de Mello V.D. Vaittinen M. Perfilyev A. Hanhineva K. Ling C. Pihlajamaki J. Liver DNA methylation of FADS2 associates with FADS2 genotype Clin. Epigenet. 2019 11 10 10.1186/s13148-019-0609-1 30654845

상세보기
32. Kaelin W.G. Jr. McKnight S.L. Influence of metabolism on epigenetics and disease Cell 2013 153 56 69 10.1016/j.cell.2013.03.004 23540690

상세보기
33. Lu C. Thompson C.B. Metabolic regulation of epigenetics Cell Metab. 2012 16 9 17 10.1016/j.cmet.2012.06.001 22768835

상세보기
34. Seto E. Yoshida M. Erasers of histone acetylation: The histone deacetylase enzymes Cold Spring Harb. Perspect. Biol. 2014 6 a018713 10.1101/cshperspect.a018713 24691964

상세보기
35. Niki T. Rombouts K. De Bleser P. De Smet K. Rogiers V. Schuppan D. Yoshida M. Gabbiani G. Geerts A. A histone deacetylase inhibitor, trichostatin a, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture Hepatology 1999 29 858 867 10.1002/hep.510290328 10051490

상세보기
36. Park K.C. Park J.H. Jeon J.Y. Kim S.Y. Kim J.M. Lim C.Y. Lee T.H. Kim H.K. Lee H.G. Kim S.M. A new histone deacetylase inhibitor improves liver fibrosis in BDL rats through suppression of hepatic stellate cells Br. J. Pharmacol. 2014 171 4820 4830 10.1111/bph.12590 24467283

상세보기
37. Tian Y. Wong V.W. Wong G.L. Yang W. Sun H. Shen J. Tong J.H. Go M.Y. Cheung Y.S. Lai P.B. Histone deacetylase HDAC8 promotes insulin resistance and beta-catenin activation in NAFLD-associated hepatocellular carcinoma Cancer Res. 2015 75 4803 4816 10.1158/0008-5472.CAN-14-3786 26383163

상세보기
38. Dhalluin C. Carlson J.E. Zeng L. He C. Aggarwal A.K. Zhou M.M. Structure and ligand of a histone acetyltransferase bromodomain Nature 1999 399 491 496 10.1038/20974 10365964

상세보기
39. Belkina A.C. Denis G.V. BET domain co-regulators in obesity, inflammation and cancer Nat. Rev. Cancer 2012 12 465 477 10.1038/nrc3256 22722403

상세보기
40. Theodoulou N.H. Tomkinson N.C. Prinjha R.K. Humphreys P.G. Clinical progress and pharmacology of small molecule bromodomain inhibitors Curr. Opin. Chem. Biol. 2016 33 58 66 10.1016/j.cbpa.2016.05.028 27295577

상세보기
41. Ding N. Hah N. Yu R.T. Sherman M.H. Benner C. Leblanc M. He M. Liddle C. Downes M. Evans R.M. BRD4 is a novel therapeutic target for liver fibrosis Proc. Natl. Acad. Sci. USA 2015 112 15713 15718 10.1073/pnas.1522163112 26644586

상세보기
42. Jambhekar A. Dhall A. Shi Y. Roles and regulation of histone methylation in animal development Nat. Rev. Mol. Cell Biol. 2019 20 625 641 10.1038/s41580-019-0151-1 31267065

상세보기
43. Klose R.J. Kallin E.M. Zhang Y. JmjC-domain-containing proteins and histone demethylation Nat. Rev. Genet. 2006 7 715 727 10.1038/nrg1945 16983801

상세보기
44. Bricambert J. Alves-Guerra M.C. Esteves P. Prip-Buus C. Bertrand-Michel J. Guillou H. Chang C.J. Vander Wal M.N. Canonne-Hergaux F. Mathurin P. The histone demethylase Phf2 acts as a molecular checkpoint to prevent NAFLD progression during obesity Nat. Commun. 2018 9 2092 10.1038/s41467-018-04361-y 29844386

상세보기
45. Page A. Paoli P.P. Hill S.J. Howarth R. Wu R. Kweon S.M. French J. White S. Tsukamoto H. Mann D.A. Alcohol directly stimulates epigenetic modifications in hepatic stellate cells J. Hepatol. 2015 62 388 397 10.1016/j.jhep.2014.09.033 25457206

상세보기
46. Perugorria M.J. Wilson C.L. Zeybel M. Walsh M. Amin S. Robinson S. White S.A. Burt A.D. Oakley F. Tsukamoto H. Histone methyltransferase ash1 orchestrates fibrogenic gene transcription during myofibroblast transdifferentiation Hepatology 2012 56 1129 1139 10.1002/hep.25754 22488473

상세보기
47. Argemi J. Bataller R. Identifying new epigenetic drivers of liver fibrosis Cell Mol. Gastroenterol. Hepatol. 2019 7 237 238 10.1016/j.jcmgh.2018.09.015 30539791

상세보기
48. Ringrose L. Paro R. Epigenetic regulation of cellular memory by the polycomb and trithorax group proteins Ann. Rev. Genet. 2004 38 413 443 10.1146/annurev.genet.38.072902.091907 15568982

상세보기
49. Francis N.J. Kingston R.E. Woodcock C.L. Chromatin compaction by a polycomb group protein complex Science 2004 306 1574 1577 10.1126/science.1100576 15567868

상세보기
50. Bernstein B.E. Mikkelsen T.S. Xie X. Kamal M. Huebert D.J. Cuff J. Fry B. Meissner A. Wernig M. Plath K. A bivalent chromatin structure marks key developmental genes in embryonic stem cells Cell 2006 125 315 326 10.1016/j.cell.2006.02.041 16630819

상세보기
51. Di Croce L. Helin K. Transcriptional regulation by polycomb group proteins Nat. Struct. Mol. Biol. 2013 20 1147 1155 10.1038/nsmb.2669 24096405

상세보기
52. Margueron R. Li G. Sarma K. Blais A. Zavadil J. Woodcock C.L. Dynlacht B.D. Reinberg D. Ezh1 and Ezh2 maintain repressive chromatin through different mechanisms Mol. Cell 2008 32 503 518 10.1016/j.molcel.2008.11.004 19026781

상세보기
53. Gunawan M. Venkatesan N. Loh J.T. Wong J.F. Berger H. Neo W.H. Li L.Y. La Win M.K. Yau Y.H. Guo T. The methyltransferase Ezh2 controls cell adhesion and migration through direct methylation of the extranuclear regulatory protein talin Nat. Immunol. 2015 16 505 516 10.1038/ni.3125 25751747

상세보기
54. Kim E. Kim M. Woo D.H. Shin Y. Shin J. Chang N. Oh Y.T. Kim H. Rheey J. Nakano I. Phosphorylation of EZH2 activates STAT3 signaling via stat3 methylation and promotes tumorigenicity of glioblastoma stem-like cells Cancer Cell 2013 23 839 852 10.1016/j.ccr.2013.04.008 23684459

상세보기
55. Su I.H. Dobenecker M.W. Dickinson E. Oser M. Basavaraj A. Marqueron R. Viale A. Reinberg D. Wulfing C. Tarakhovsky A. Polycomb group protein Ezh2 controls actin polymerization and cell signaling Cell 2005 121 425 436 10.1016/j.cell.2005.02.029 15882624

상세보기
56. Vasanthakumar A. Xu D. Lun A.T. Kueh A.J. van Gisbergen K.P. Iannarella N. Li X. Yu L. Wang D. Williams B.R. A non-canonical function of Ezh2 preserves immune homeostasis EMBO Rep. 2017 18 619 631 10.15252/embr.201643237 28223321

상세보기
57. Xu K. Wu Z.J. Groner A.C. He H.H. Cai C. Lis R.T. Wu X. Stack E.C. Loda M. Liu T. EZH2 oncogenic activity in castration-resistant prostate cancer cells is polycomb-independent Science 2012 338 1465 1469 10.1126/science.1227604 23239736

상세보기
58. Batool A. Jin C. Liu Y.X. Role of EZH2 in cell lineage determination and relative signaling pathways Front. Biosci. 2019 24 947 960 10.2741/4760

상세보기
59. Hu X. Eastman A.E. Guo S. Cell cycle dynamics in the reprogramming of cellular identity FEBS Lett. 2019 593 2840 2852 10.1002/1873-3468.13625 31562821

상세보기
60. Yao Y. Hu H. Yang Y. Zhou G. Shang Z. Yang X. Sun K. Zhan S. Yu Z. Li P. Downregulation of enhancer of zeste homolog 2 (EZH2) is essential for the induction of autophagy and apoptosis in colorectal cancer cells Genes 2016 7 83 10.3390/genes7100083

상세보기
61. Michalopoulos G.K. DeFrances M.C. Liver regeneration Science 1997 276 60 66 10.1126/science.276.5309.60 9082986

상세보기
62. Fausto N. Liver regeneration and repair: Hepatocytes, progenitor cells, and stem cells Hepatology 2004 39 1477 1487 10.1002/hep.20214 15185286

상세보기
63. Fausto N. Campbell J.S. Riehle K.J. Liver regeneration Hepatology 2006 43 S45 S53 10.1002/hep.20969 16447274

상세보기
64. Aoki R. Chiba T. Miyagi S. Negishi M. Konuma T. Taniguchi H. Ogawa M. Yokosuka O. Iwama A. The polycomb group gene product Ezh2 regulates proliferation and differentiation of murine hepatic stem/progenitor cells J. Hepatol. 2010 52 854 863 10.1016/j.jhep.2010.01.027 20395008

상세보기
65. Koike H. Ouchi R. Ueno Y. Nakata S. Obana Y. Sekine K. Zheng Y.W. Takebe T. Isono K. Koseki H. Polycomb group protein Ezh2 regulates hepatic progenitor cell proliferation and differentiation in murine embryonic liver PLoS ONE 2014 9 e104776 10.1371/journal.pone.0104776 25153170

상세보기
66. Bae W.K. Kang K. Yu J.H. Yoo K.H. Factor V.M. Kaji K. Matter M. Thorgeirsson S. Hennighausen L. The methyltransferases enhancer of zeste homolog (EZH) 1 and EZH2 control hepatocyte homeostasis and regeneration FASEB J. 2015 29 1653 1662 10.1096/fj.14-261537 25477280

상세보기
67. Grindheim J.M. Nicetto D. Donahue G. Zaret K.S. Polycomb repressive complex 2 proteins EZH1 and EZH2 regulate timing of postnatal hepatocyte maturation and fibrosis by repressing genes with euchromatic promoters in mice Gastroenterology 2019 156 1834 1848 10.1053/j.gastro.2019.01.041 30689973

상세보기
68. Cai M.Y. Tong Z.T. Zheng F. Liao Y.J. Wang Y. Rao H.L. Chen Y.C. Wu Q.L. Liu Y.H. Guan X.Y. EZH2 protein: A promising immunomarker for the detection of hepatocellular carcinomas in liver needle biopsies Gut 2011 60 967 976 10.1136/gut.2010.231993 21330577

상세보기
69. Au S.L. Wong C.C. Lee J.M. Fan D.N. Tsang F.H. Ng I.O. Wong C.M. Enhancer of zeste homolog 2 epigenetically silences multiple tumor suppressor micrornas to promote liver cancer metastasis Hepatology 2012 56 622 631 10.1002/hep.25679 22370893

상세보기
70. Chen S. Pu J. Bai J. Yin Y. Wu K. Wang J. Shuai X. Gao J. Tao K. Wang G. EZH2 promotes hepatocellular carcinoma progression through modulating miR-22/galectin-9 axis J. Exp. Clin. Cancer Res. 2018 37 3 10.1186/s13046-017-0670-6 29316949

상세보기
71. Liu H. Liu Y. Liu W. Zhang W. Xu J. EZH2-mediated loss of miR-622 determines cxcr4 activation in hepatocellular carcinoma Nat. Commun. 2015 6 8494 10.1038/ncomms9494 26404566

상세보기
72. Feng H. Yu Z. Tian Y. Lee Y.Y. Li M.S. Go M.Y. Cheung Y.S. Lai P.B. Chan A.M. To K.F. A CCRK-EZH2 epigenetic circuitry drives hepatocarcinogenesis and associates with tumor recurrence and poor survival of patients J. Hepatol. 2015 62 1100 1111 10.1016/j.jhep.2014.11.040 25500144

상세보기
73. Mann J. Chu D.C. Maxwell A. Oakley F. Zhu N.L. Tsukamoto H. Mann D.A. MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis Gastroenterology 2010 138 705 714 705？714, 714.e1-4 10.1053/j.gastro.2009.10.002 19843474

상세보기
74. Hazra S. Xiong S. Wang J. Rippe R.A. Krishna V. Chatterjee K. Tsukamoto H. Peroxisome proliferator-activated receptor gamma induces a phenotypic switch from activated to quiescent hepatic stellate cells J. Biol. Chem. 2004 279 11392 11401 10.1074/jbc.M310284200 14702344

상세보기
75. Yang Y. Chen X.X. Li W.X. Wu X.Q. Huang C. Xie J. Zhao Y.X. Meng X.M. Li J. EZH2-mediated repression of Dkk1 promotes hepatic stellate cell activation and hepatic fibrosis J. Cell Mol. Med. 2017 21 2317 2328 10.1111/jcmm.13153 28332284

상세보기
76. Zhao H. Wang Z. Tang F. Zhao Y. Feng D. Li Y. Hu Y. Wang C. Zhou J. Tian X. Carnosol-mediated Sirtuin 1 activation inhibits Enhancer of Zeste Homolog 2 to attenuate liver fibrosis Pharmacol. Res. 2018 128 327 337 10.1016/j.phrs.2017.10.013 29106960

상세보기
77. Dooley S. ten Dijke P. Tgf-beta in progression of liver disease Cell Tissue Res. 2012 347 245 256 10.1007/s00441-011-1246-y 22006249

상세보기
78. Castilla A. Prieto J. Fausto N. Transforming growth factors beta 1 and alpha in chronic liver disease. Effects of interferon alfa therapy N. Engl. J. Med. 1991 324 933 940 10.1056/NEJM199104043241401 1900574

상세보기
79. Friedman S.L. Hepatic stellate cells: Protean, multifunctional, and enigmatic cells of the liver Physiol. Rev. 2008 88 125 172 10.1152/physrev.00013.2007 18195085

상세보기
80. Martin-Mateos R. De Assuncao T.M. Arab J.P. Jalan-Sakrikar N. Yaqoob U. Greuter T. Verma V.K. Mathison A.J. Cao S. Lomberk G. Enhancer of zeste homologue 2 inhibition attenuates TGF-beta dependent hepatic stellate cell activation and liver fibrosis Cell Mol. Gastroenterol. Hepatol. 2019 7 197 209 10.1016/j.jcmgh.2018.09.005 30539787

상세보기
81. Vella S. Gnani D. Crudele A. Ceccarelli S. De Stefanis C. Gaspari S. Nobili V. Locatelli F. Marquez V.E. Rota R. EZH2 down-regulation exacerbates lipid accumulation and inflammation in in vitro and in vivo NAFLD Int. J. Mol. Sci. 2013 14 24154 24168 10.3390/ijms141224154 24351808

상세보기
82. Lee S. Woo D.C. Kang J. Ra M. Kim K.H. Lee S.R. Choi D.K. Lee H. Hong K.B. Min S.H. The role of the histone methyltransferase EZH2 in liver inflammation and fibrosis in STAM NASH mice Biology 2020 9 93 10.3390/biology9050093 32370249

상세보기
83. Furman B.L. Streptozotocin-induced diabetic models in mice and rats Curr. Protoc. Pharmacol. 2015 70 5.47.1 5.47.20 10.1002/0471141755.ph0547s70 26331889

상세보기
84. Saito K. Uebanso T. Maekawa K. Ishikawa M. Taguchi R. Nammo T. Nishimaki-Mogami T. Udagawa H. Fujii M. Shibazaki Y. Characterization of hepatic lipid profiles in a mouse model with nonalcoholic steatohepatitis and subsequent fibrosis Sci. Rep. 2015 5 12466 10.1038/srep12466 26289793

상세보기
85. Tam E.K. Nguyen T.M. Lim C.Z. Lee P.L. Li Z. Jiang X. Santhanakrishnan S. Tan T.W. Goh Y.L. Wong S.Y. 3-deazaneplanocin a and neplanocin a analogues and their effects on apoptotic cell death ChemMedChem 2015 10 173 182 10.1002/cmdc.201402315 25319940

상세보기
86. Fujiwara T. Saitoh H. Inoue A. Kobayashi M. Okitsu Y. Katsuoka Y. Fukuhara N. Onishi Y. Ishizawa K. Ichinohasama R. 3-deazaneplanocin a (DZNep), an inhibitor of s-adenosylmethionine-dependent methyltransferase, promotes erythroid differentiation J. Biol. Chem. 2014 289 8121 8134 10.1074/jbc.M114.548651 24492606

상세보기
87. Zeybel M. Luli S. Sabater L. Hardy T. Oakley F. Leslie J. Page A. Moran Salvador E. Sharkey V. Tsukamoto H. A proof-of-concept for epigenetic therapy of tissue fibrosis: Inhibition of liver fibrosis progression by 3-deazaneplanocin a Mol. Ther. 2017 25 218 231 10.1016/j.ymthe.2016.10.004 28129116

상세보기
88. Knutson S.K. Wigle T.J. Warholic N.M. Sneeringer C.J. Allain C.J. Klaus C.R. Sacks J.D. Raimondi A. Majer C.R. Song J. A selective inhibitor of EZH2 blocks H3K27 methylation and kills mutant lymphoma cells Nat. Chem. Biol. 2012 8 890 896 10.1038/nchembio.1084 23023262

상세보기
89. Qi W. Chan H. Teng L. Li L. Chuai S. Zhang R. Zeng J. Li M. Fan H. Lin Y. Selective inhibition of Ezh2 by a small molecule inhibitor blocks tumor cells proliferation Proc. Natl. Acad. Sci. USA 2012 109 21360 21365 10.1073/pnas.1210371110 23236167

상세보기
90. McCabe M.T. Ott H.M. Ganji G. Korenchuk S. Thompson C. Van Aller G.S. Liu Y. Graves A.P. Della Pietra A. 3rd Diaz E. EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations Nature 2012 492 108 112 10.1038/nature11606 23051747

상세보기
91. Zhou T. Sun Y. Li M. Ding Y. Yin R. Li Z. Xie Q. Bao S. Cai W. Enhancer of zeste homolog 2-catalysed H3K27 trimethylation plays a key role in acute-on-chronic liver failure via TNF-mediated pathway Cell Death Dis. 2018 9 590 10.1038/s41419-018-0670-2 29789597

상세보기
92. Konze K.D. Ma A. Li F. Barsyte-Lovejoy D. Parton T. Macnevin C.J. Liu F. Gao C. Huang X.P. Kuznetsova E. An orally bioavailable chemical probe of the lysine methyltransferases EZH2 and EZH1 ACS Chem. Biol. 2013 8 1324 1334 10.1021/cb400133j 23614352

상세보기
93. Knutson S.K. Warholic N.M. Wigle T.J. Klaus C.R. Allain C.J. Raimondi A. Porter Scott M. Chesworth R. Moyer M.P. Copeland R.A. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2 Proc. Natl. Acad. Sci. USA 2013 110 7922 7927 10.1073/pnas.1303800110 23620515

상세보기
94. Knutson S.K. Kawano S. Minoshima Y. Warholic N.M. Huang K.C. Xiao Y. Kadowaki T. Uesugi M. Kuznetsov G. Kumar N. Selective inhibition of EZH2 by EPZ-6438 leads to potent antitumor activity in ezh2-mutant non-hodgkin lymphoma Mol. Cancer Ther. 2014 13 842 854 10.1158/1535-7163.MCT-13-0773 24563539

상세보기
95. Hoy S.M. Tazemetostat: First approval Drugs 2020 80 513 521 10.1007/s40265-020-01288-x 32166598

상세보기
96. Tan J. Yang X. Zhuang L. Jiang X. Chen W. Lee P.L. Karuturi R.K. Tan P.B. Liu E.T. Yu Q. Pharmacologic disruption of polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells Genes Dev. 2007 21 1050 1063 10.1101/gad.1524107 17437993

상세보기
97. Beguelin W. Popovic R. Teater M. Jiang Y. Bunting K.L. Rosen M. Shen H. Yang S.N. Wang L. Ezponda T. EZH2 is required for germinal center formation and somatic EZH2 mutations promote lymphoid transformation Cancer Cell 2013 23 677 692 10.1016/j.ccr.2013.04.011 23680150

상세보기
98. Shahabipour F. Caraglia M. Majeed M. Derosa G. Maffioli P. Sahebkar A. Naturally occurring anti-cancer agents targeting EZH2 Cancer Lett. 2017 400 325 335 10.1016/j.canlet.2017.03.020 28323035

상세보기
99. Zhu C. Cao H. Zhou X. Dong C. Luo J. Zhang C. Liu J. Ling Y. Meta-analysis of the clinical value of danshen injection and huangqi injection in liver cirrhosis Evid. Based Complement. Alternat. Med. 2013 2013 842824 10.1155/2013/842824 24069058

상세보기
100. Woo J. Kim H.Y. Byun B.J. Chae C.H. Lee J.Y. Ryu S.Y. Park W.K. Cho H. Choi G. Biological evaluation of tanshindiols as EZH2 histone methyltransferase inhibitors Bioorg. Med. Chem. Lett. 2014 24 2486 2492 10.1016/j.bmcl.2014.04.010 24767850

상세보기
101. Shen L. Liu C.C. An C.Y. Ji H.F. How does curcumin work with poor bioavailability? Clues from experimental and theoretical studies Sci. Rep. 2016 6 20872 10.1038/srep20872 26887346

상세보기
102. Maheshwari R.K. Singh A.K. Gaddipati J. Srimal R.C. Multiple biological activities of curcumin: A short review Life Sci. 2006 78 2081 2087 10.1016/j.lfs.2005.12.007 16413584

상세보기
103. Rahmani S. Asgary S. Askari G. Keshvari M. Hatamipour M. Feizi A. Sahebkar A. Treatment of non-alcoholic fatty liver disease with curcumin: A randomized placebo-controlled trial Phytother. Res. 2016 30 1540 1548 10.1002/ptr.5659 27270872

상세보기
104. Hua W.F. Fu Y.S. Liao Y.J. Xia W.J. Chen Y.C. Zeng Y.X. Kung H.F. Xie D. Curcumin induces down-regulation of EZH2 expression through the MAPK pathway in MDA-MB-435 human breast cancer cells Eur. J. Pharmacol. 2010 637 16 21 10.1016/j.ejphar.2010.03.051 20385124

상세보기
105. Wu G.Q. Chai K.Q. Zhu X.M. Jiang H. Wang X. Xue Q. Zheng A.H. Zhou H.Y. Chen Y. Chen X.C. Anti-cancer effects of curcumin on lung cancer through the inhibition of EZH2 and NOTCH1 Oncotarget 2016 7 26535 26550 10.18632/oncotarget.8532 27049834

상세보기
106. Mansour-Ghanaei F. Hadi A. Pourmasoumi M. Joukar F. Golpour S. Najafgholizadeh A. Green tea as a safe alternative approach for nonalcoholic fatty liver treatment: A systematic review and meta-analysis of clinical trials Phytother. Res. 2018 32 1876 1884 10.1002/ptr.6130 29947156

상세보기
107. Shimizu M. Fukutomi Y. Ninomiya M. Nagura K. Kato T. Araki H. Suganuma M. Fujiki H. Moriwaki H. Green tea extracts for the prevention of metachronous colorectal adenomas: A pilot study Cancer Epidemiol. Biomark. Prev. 2008 17 3020 3025 10.1158/1055-9965.EPI-08-0528

상세보기
108. Borutinskaite V. Virksaite A. Gudelyte G. Navakauskiene R. Green tea polyphenol egcg causes anti-cancerous epigenetic modulations in acute promyelocytic leukemia cells Leuk. Lymphoma 2018 59 469 478 10.1080/10428194.2017.1339881 28641467

상세보기
109. Lau J.K. Zhang X. Yu J. Animal models of non-alcoholic fatty liver disease: Current perspectives and recent advances J. Pathol. 2017 241 36 44 10.1002/path.4829 27757953

상세보기
110. Ouchi R. Togo S. Kimura M. Shinozawa T. Koido M. Koike H. Thompson W. Karns R.A. Mayhew C.N. McGrath P.S. Modeling steatohepatitis in humans with pluripotent stem cell-derived organoids Cell Metab. 2019 30 374 384.e376 10.1016/j.cmet.2019.05.007 31155493

상세보기
111. Mun S.J. Ryu J.S. Lee M.O. Son Y.S. Oh S.J. Cho H.S. Son M.Y. Kim D.S. Kim S.J. Yoo H.J. Generation of expandable human pluripotent stem cell-derived hepatocyte-like liver organoids J. Hepatol. 2019 71 970 985 10.1016/j.jhep.2019.06.030 31299272

상세보기
112. Kim W. Bird G.H. Neff T. Guo G. Kerenyi M.A. Walensky L.D. Orkin S.H. Targeted disruption of the EZH2-EED complex inhibits EZH2-dependent cancer Nat. Chem. Biol. 2013 9 643 650 10.1038/nchembio.1331 23974116

상세보기
113. Xiao L. Tien J.C. Vo J. Tan M. Parolia A. Zhang Y. Wang L. Qiao Y. Shukla S. Wang X. Epigenetic reprogramming with antisense oligonucleotides enhances the effectiveness of androgen receptor inhibition in castration-resistant prostate cancer Cancer Res. 2018 78 5731 5740 10.1158/0008-5472.CAN-18-0941 30135193

상세보기
114. Duan R. Du W. Guo W. EZH2: A novel target for cancer treatment J. Hematol. Oncol. 2020 13 104 10.1186/s13045-020-00937-8 32723346

상세보기

LOADING...

활용도 분석정보

상세보기

다운로드

내보내기

활용도 Top5 논문

해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.

표제어: PCR

동의어: Packet Collision Rate

용어 설명 출처 목록 (6)

용어 설명: PCR은 세균 특이성이 있는 primer를 이용하여 적은 수의 세균이 있을지라도 쉽게 검출할 수 있는 유용한 방법이며, 이를 이용하여 구강 내 치면세균막이나 타액에서 직접 세균을 검출할 수 있게 되었다[8].

내보내기 구분	파일저장 인쇄 메일전송
구성항목	기본정보 상세정보 관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관 관리번호, 논문명, 대등논문명, 저자 , 저널/프로시딩명, 발행기관, 발행년, 발행언어, 권, 호, 시작페이지, 끝페이지, ISBN, ISSN, 주제분야, 키워드, 초록(한글), 초록(영문), 저자(소속기관)
저장형식	Text(ASCII format) Excel format RefWorks Direct Export RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley
메일정보	받는사람 (필수) @ 보내는사람 (선택) @ 제목 내용 KISTI 검색결과 이메일 서비스
안내	총 건의 자료가 검색되었습니다. 다운받으실 자료의 인덱스를 입력하세요. (1-10,000) 검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다. 데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요) 다운로드 파일은 UTF-8 형태로 저장됩니다. 파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오. ~ Text(ASCII format) Excel format

연합인증